Matches in Wikidata for { <http://www.wikidata.org/entity/Q48382339> ?p ?o ?g. }
- Q48382339 description "2012 nî lūn-bûn" @default.
- Q48382339 description "2012年の論文" @default.
- Q48382339 description "2012年学术文章" @default.
- Q48382339 description "2012年学术文章" @default.
- Q48382339 description "2012年学术文章" @default.
- Q48382339 description "2012年学术文章" @default.
- Q48382339 description "2012年学术文章" @default.
- Q48382339 description "2012年学术文章" @default.
- Q48382339 description "2012年學術文章" @default.
- Q48382339 description "2012年學術文章" @default.
- Q48382339 description "2012年學術文章" @default.
- Q48382339 description "2012年學術文章" @default.
- Q48382339 description "2012年學術文章" @default.
- Q48382339 description "2012년 논문" @default.
- Q48382339 description "article científic" @default.
- Q48382339 description "article scientific" @default.
- Q48382339 description "article scientifique" @default.
- Q48382339 description "articol științific" @default.
- Q48382339 description "articolo scientifico" @default.
- Q48382339 description "artigo científico" @default.
- Q48382339 description "artigo científico" @default.
- Q48382339 description "artigo científico" @default.
- Q48382339 description "artikel ilmiah" @default.
- Q48382339 description "artikull shkencor" @default.
- Q48382339 description "artikulong pang-agham" @default.
- Q48382339 description "artykuł naukowy" @default.
- Q48382339 description "artículo científico publicado en 2012" @default.
- Q48382339 description "artículu científicu" @default.
- Q48382339 description "bilimsel makale" @default.
- Q48382339 description "bài báo khoa học" @default.
- Q48382339 description "naučni članak" @default.
- Q48382339 description "scienca artikolo" @default.
- Q48382339 description "scientific article published on 23 September 2012" @default.
- Q48382339 description "scientific article published on 23 September 2012" @default.
- Q48382339 description "scientific article published on 23 September 2012" @default.
- Q48382339 description "teaduslik artikkel" @default.
- Q48382339 description "tieteellinen artikkeli" @default.
- Q48382339 description "tudományos cikk" @default.
- Q48382339 description "vedecký článok" @default.
- Q48382339 description "vetenskaplig artikel" @default.
- Q48382339 description "videnskabelig artikel" @default.
- Q48382339 description "vitenskapelig artikkel" @default.
- Q48382339 description "vitskapeleg artikkel" @default.
- Q48382339 description "vědecký článek" @default.
- Q48382339 description "wetenschappelijk artikel" @default.
- Q48382339 description "wissenschaftlicher Artikel" @default.
- Q48382339 description "επιστημονικό άρθρο" @default.
- Q48382339 description "мақолаи илмӣ" @default.
- Q48382339 description "наукова стаття, опублікована у вересні 2012" @default.
- Q48382339 description "научна статия" @default.
- Q48382339 description "научная статья" @default.
- Q48382339 description "научни чланак" @default.
- Q48382339 description "научни чланак" @default.
- Q48382339 description "מאמר מדעי" @default.
- Q48382339 description "مقالة علمية نشرت في 23 سبتمبر 2012" @default.
- Q48382339 description "২৩ সেপ্টেম্বর ২০১২-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
- Q48382339 description "บทความทางวิทยาศาสตร์" @default.
- Q48382339 description "სამეცნიერო სტატია" @default.
- Q48382339 name "Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05)." @default.
- Q48382339 name "Bevacizumab and erlotinib" @default.
- Q48382339 type Item @default.
- Q48382339 label "Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05)." @default.
- Q48382339 label "Bevacizumab and erlotinib" @default.
- Q48382339 prefLabel "Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05)." @default.
- Q48382339 prefLabel "Bevacizumab and erlotinib" @default.
- Q48382339 P1433 Q48382339-3B15D0C8-81F9-4936-8074-18F8233854E2 @default.
- Q48382339 P1476 Q48382339-A2771A5E-DB60-4E15-B9D7-9204ACFAA317 @default.
- Q48382339 P2093 Q48382339-08C3A183-4C71-4691-AC3B-75E7F45FE618 @default.
- Q48382339 P2093 Q48382339-0EDCED0E-1AA6-445F-BBDB-50B9738D5C62 @default.
- Q48382339 P2093 Q48382339-1A6DAB72-D07F-44ED-9ED1-6962FDC68F76 @default.
- Q48382339 P2093 Q48382339-4069C10D-57B2-4EBE-B461-ECEDB5CC8E0E @default.
- Q48382339 P2093 Q48382339-4E2A187F-A1CF-41EF-910D-8B02E4959A47 @default.
- Q48382339 P2093 Q48382339-6C257E59-39F7-424E-90E5-61AB71A9BC24 @default.
- Q48382339 P2093 Q48382339-6C5CD9AE-DA2D-42A8-BC88-C562DADA028C @default.
- Q48382339 P2093 Q48382339-6E6D217F-28E0-4035-AA34-DB44894716DE @default.
- Q48382339 P2093 Q48382339-6F9137B8-6403-4D15-AA67-E33EE9829406 @default.
- Q48382339 P2093 Q48382339-70CCBE61-62EB-4D44-9E98-16A63AF4E044 @default.
- Q48382339 P2093 Q48382339-7971F246-7052-4EA3-AAB9-3F9A868B5606 @default.
- Q48382339 P2093 Q48382339-A979070B-A745-4045-9D52-A43EBE651703 @default.
- Q48382339 P2093 Q48382339-AF8A75A1-EB7A-4EF8-9632-B9079FBAEA66 @default.
- Q48382339 P2093 Q48382339-E2049424-228F-4890-A56E-C27E620F91FC @default.
- Q48382339 P2093 Q48382339-E83DFB9A-0341-4642-A730-89B5FC9F80EA @default.
- Q48382339 P304 Q48382339-A52E0865-65EF-48BC-B643-92A13AB888CA @default.
- Q48382339 P31 Q48382339-0BEBEEB2-3AF1-4788-B04D-BA7A9FCB97AC @default.
- Q48382339 P356 Q48382339-8FB8663E-792C-4E25-9E68-659476E62A28 @default.
- Q48382339 P433 Q48382339-CFB91ADB-4C6B-4FC4-992C-780E401A7C1C @default.
- Q48382339 P478 Q48382339-2DF6FC0A-3BE4-47E5-A099-285C50A30448 @default.
- Q48382339 P50 Q48382339-06BBEDCF-43B7-4F32-B093-48C0C390DFC2 @default.
- Q48382339 P50 Q48382339-28E22F73-5CD5-4368-A784-28BF70BDE377 @default.
- Q48382339 P50 Q48382339-35B9B78A-35DD-4609-94BD-73D6377CC09A @default.
- Q48382339 P50 Q48382339-981F8913-CBC1-4471-9010-06AE99B2357C @default.
- Q48382339 P577 Q48382339-13681A9C-3AFD-4829-A95A-1ED9B43F7023 @default.
- Q48382339 P698 Q48382339-7FD17229-DE4D-497A-BF7B-883F27C7ACDD @default.
- Q48382339 P921 Q48382339-56CB3D55-F297-4E14-B832-DFD953031FC2 @default.
- Q48382339 P921 Q48382339-6BD61A88-1DAC-4FC7-A696-FF48081F8993 @default.
- Q48382339 P921 Q48382339-BE14963D-2C3F-4D0D-BA4A-135F60488531 @default.
- Q48382339 P356 J.LUNGCAN.2012.08.017 @default.
- Q48382339 P698 23009726 @default.
- Q48382339 P1433 Q641464 @default.
- Q48382339 P1476 "Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05)." @default.